Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Avidity Biosciences

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities3.40%
Size of stake in company1.60%
Market capitalizationUSD 6.0 bn

Sector

Rare genetic muscle diseases 

Main candidate

Del-desiran (AOC 1001)

Main indications

Myotonic dystrophy type 

About the company

Avidity Biosciences is a biotechnology company that focuses on developing RNA-based therapeutics for rare neuromuscular diseases. The company’s work centers around its proprietary AOC™ (Antibody Oligonucleotide Conjugates) platform, which enables targeted delivery of oligonucleotides to specific tissues. Its lead clinical candidate, del-desiran (AOC 1001), is currently in development for the treatment of myotonic dystrophy type 1 (DM1). The pipeline also includes programs for other rare muscle disorders, such as FSHD (facioscapulohumeral muscular dystrophy) with del-brax (AOC 1020), and Duchenne muscular dystrophy (DMD) with del-zota (AOC 1044), particularly for patients amenable to exon 44 skipping. In addition, Avidity is expanding its AOC platform to address other genetic and inflammatory diseases.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.